AGP Executive Report

Bereavement Support: Austria is set to offer paid bereavement leave for women who suffer miscarriages, aiming to better protect mental health and recovery after pregnancy loss. Mental Health After Violence: In the wake of a deadly Vienna, Georgia block-party shooting (2 dead, 35 injured), the US Disaster Distress Helpline is urging immediate crisis counseling for survivors, first responders, and witnesses. Public Safety & Trauma: Authorities say deputies were already on patrol when gunfire erupted at a crowded homecoming weekend gathering, with conditions ranging from stable to critical and no motive yet released. Religious Freedom Debate: Cardinal Gerhard Müller urged Catholics to attend pro-life rallies in Vienna and across Europe, warning that “protection zones” around abortion facilities could threaten religious freedom. Health Research in Austria: MedUni Vienna researchers report that maternal immune cells (neutrophils) can be reprogrammed to support early placental development, shifting from inflammation to key pregnancy processes. Dermatology Advances (Vienna): At EADV 2026 in Vienna, new data highlighted next-generation targeted treatments for conditions like atopic dermatitis and psoriasis, reflecting a move toward more durable, biologic-based care.

Public Safety: A mass shooting in Vienna, Georgia left 2 dead and 35 injured after gunfire erupted at a neighborhood homecoming street party early Sunday; authorities say 50+ shots were fired across at least two nearby locations, with victims taken to multiple hospitals and no arrests or motive confirmed yet. Digital Health: A new The Lancet review warns that problematic digital media use is linked to higher risks for mental health issues, sleep problems, and less physical activity in young people, arguing harms stem from tech business models and weak governance—not personal willpower—and calls for coordinated public health regulation. Medical Innovation (Austria-linked): At EURETINA 2026 in Vienna, AAVantgarde reported updated clinical and preclinical data for gene therapies targeting inherited retinal diseases, including early safety and visual-function signals in a Usher type B study. Health Systems & Vaccines: Nigeria’s regulator NAFDAC is seeking international partners to support local vaccine manufacturing to reach WHO maturity goals—an effort that highlights how supply and regulatory capacity shape public health readiness.

Dermatology at EADV 2026 (Vienna): New data from the European Academy of Dermatology and Venereology Congress is putting a spotlight on how skin disease varies by biology and patient profile, with sessions linking atopic dermatitis to barrier dysfunction and targeted anti-inflammatory options, plus real-world evidence alongside clinical trials. GLP-1 side effects (skin): An international EADV survey reported nail detachment in about 39% of GLP-1 users versus 9% of nonusers, and also flagged related hair/scalp changes. Psoriasis drug race: Late-breaker results at EADV showed zasocitinib outperforming deucravacitinib on top psoriasis clearance targets at week 16, adding to the growing oral TYK2 competition. Public health & policy: A push for permanent daylight saving time is framed as a health issue, with concerns about sleep and circadian rhythm disruption. Safety and violence (Vienna, Georgia): A mass shooting at a homecoming block party left 2 dead and up to 35 injured; investigators say deputies were patrolling when shots were fired, with no suspects or motive released yet.

Heat & Public Health: Austria’s heat toll hit a grim record, with AGES estimating 995 heat-related deaths from June–August 2026—nearly 1,000—after the country’s hottest summer on record. Dermatology in Vienna (EADV): New real-world and trial updates dominated the EADV Congress in Vienna, including delgocitinib real-world results for chronic hand eczema and multiple late-breaking skin-disease findings. Vitiligo Drug News: Pfizer reported Phase 3 results for oral ritlecitinib (LITFULO) showing higher facial and total-body repigmentation in nonsegmental vitiligo across its TRANQUILLO programs. Atopic Dermatitis Pipeline: EADV coverage also highlighted new data around IL-4/IL-13 pathway targeting (including telikibart) and comparative analyses for oral upadacitinib versus nemolizumab. GLP-1 Side Effects: A new analysis linked GLP-1 use to higher rates of nail detachment and hair changes, with risks persisting even after accounting for weight loss. Breast Cancer Access: Eurostat data put Austria’s mammography participation at 41.3% (50–69, within two years), while availability of mammography units varies widely across the EU.

Dermatology in Vienna: New real-world data at EADV 2026 in Austria point to delgocitinib cream improving chronic hand eczema in routine care, with itch, pain and quality of life gains also reported for adolescents. Atopic dermatitis & eczema pipeline: EADV updates include indirect comparisons suggesting upadacitinib may outperform nemolizumab on skin and itch targets, plus long-term and late-breaking results across multiple immune skin conditions. Vitiligo progress: Pfizer’s oral ritlecitinib (Litfulo) showed significantly higher facial and total body repigmentation vs placebo in the large TRANQUILLO Phase 3 program, supporting potential regulatory submissions. GLP-1 skin side effects: A new EADV-linked study reports higher rates of nail detachment and hair changes among people using GLP-1 receptor agonists, even after accounting for weight loss. Heat and health in Austria: Austria’s heat-related deaths were estimated at 995 for June–August 2026, tied to a record-hot summer. Cancer screening access: Eurostat data show Austria’s mammography screening participation at 41.3% (50–69), while access varies widely across EU countries.

Vitiligo Drug Breakthrough (Vienna): Pfizer presented late-breaking Phase 3 results at EADV in Vienna showing oral ritlecitinib (Litfulo) improved facial and total-body repigmentation in nonsegmental vitiligo, with F-VASI75 at week 52 reported at 21.9% vs 2.4% on placebo, and similar serious adverse event rates. Cutaneous Lupus Update (Vienna): Biogen reported 52-week Phase 2 AMETHYST data for litifilimab in cutaneous lupus erythematosus, with clear/almost-clear skin (CLA-IGA-R 0–1) rising to 27.2% at week 52 and no new safety signals. Atopic Dermatitis (EADV, Vienna): Eli Lilly’s lebrikizumab (Ebglyss) showed hand-and-foot eczema improvements in ADtouch, with 53% reaching clear/nearly clear at 16 weeks vs 27% on placebo. Heat and Health (Austria): Austria estimated nearly 1,000 heat-related deaths during a record-hot summer, underscoring the health risks of extreme temperatures. Cancer Screening Access (EU, incl. Austria): Eurostat data highlighted mammography capacity gaps and low participation; Austria’s screening participation was 41.3% (50–69), while Cyprus had higher unit availability but low screening uptake.

Heat & Mortality: Austria’s health agency AGES estimates nearly 1,000 heat-related deaths (995) between June and August 2026, the highest since records began in 2017, tied to the hottest summer in 260 years. Dermatology Drug Pipeline (Vienna/EADV): Eli Lilly reports phase 3b ADtouch results for Ebglyss (lebrikizumab-lbkz): 53% of patients with hand-and-foot eczema reached clear or nearly clear skin at 16 weeks vs 27% on placebo. Vitiligo Treatment Advances (Vienna/EADV): Pfizer’s oral Litfulo (ritlecitinib) shows phase 3 progress in nonsegmental vitiligo, with plans for regulatory submissions to expand options beyond current limited therapies. Cutaneous Lupus Update (Vienna/EADV): Biogen’s litifilimab posts 52-week phase 2 AMETHYST data in cutaneous lupus erythematosus, with continued skin improvements and no new safety signals. Older Persons & Longevity: International Day of Older Persons (Oct 1) spotlights the gap between life expectancy and healthy life expectancy and the need for better support systems. Cancer Prevention Clue: A large analysis links inflamed-appendix surgery (appendectomy) with a lower later colorectal cancer risk than antibiotics.

EU Health Policy: EU health ministers in Dublin debated the US “Most Favoured Nation” (MFN) idea, with concerns it could push up medicine prices and strain patient access and national budgets; Austria’s health officials also urged faster, more coordinated EU health security planning. Heat & Public Health: A Bloomberg compilation estimates over 34,600 heat-related deaths across Western Europe this summer, with Spain’s deadliest summer since 2015 and multiple countries reporting elevated tolls. Dermatology Research (Vienna/EADV): New EADV data highlighted sustained atopic dermatitis benefits from investigational treatments (including long-term itch and quality-of-life improvements) and a French study linking GLP-1 use with higher odds of nail changes and hair/scalp issues. Care Access in Conflict: Austrian Red Cross support helped Ukrainian Red Cross mobile medical teams deliver family-doctor consultations, checks, medicines, referrals and urgent care in Zaporizhia. Aging & Longevity: The UN marked International Day of Older Persons with a call to rethink systems for longer lives and strengthen intergenerational support.

Dermatology in Vienna (EADV): New late-breaking data in Austria’s dermatology spotlight point to faster, more targeted options—Evommune’s EVO301 (IL-18) showed a clear therapeutic signal in atopic dermatitis with two IV doses, while Highlight Therapeutics’ intralesional BO-112 hit a 61% response rate in resectable basal cell carcinoma, including many complete responses in head-and-neck and facial lesions. Skin safety with new meds: A study presented at EADV found nail detachment is over 4x more common with GLP-1 receptor agonists, adding practical “watch-outs” for patients starting these drugs. Ophthalmology (real-world): Roche reported new VOYAGER real-world results for Vabysmo (faricimab) across nAMD, DME and RVO, reinforcing effectiveness and durability with no new safety signals. Cancer care (Austria case report): A Krems team reported a rare remission in an aggressive lymphoma case after treatment was chosen using tumor DNA shed into blood. Public health context: Western Europe’s heat this summer drove more than 34,600 deaths, underscoring growing climate-linked health risks.

Cancer Care in Austria: A 75-year-old woman at University Hospital Krems with aggressive, repeatedly relapsing ALCL achieved complete remission for over two years after doctors sequenced tumor DNA from her blood and matched treatment to a PD-1 inhibitor (nivolumab), a rare approach reported in Cancer Reports. Dermatology in Vienna: At EADV 2026, Vienna is hosting major skin-medicine updates, including lebrikizumab (Ebglyss) improving hand-and-foot atopic dermatitis symptoms, and long-term nemolizumab (Nemluvio) durability through 3 years. Diabetes & Weight Drugs in Focus: New EASD research looks at real-world GLP-1 use in children and young people across Germany, Austria and Luxembourg. Medication Safety Tech: Clarest Health launched Clarest Path, aiming to flag medication-related risk earlier for better adherence and outcomes. EU Health Funding Debate (Gastein): At the European Health Forum Gastein, experts warned that the EU’s next budget may lack dedicated health funding, risking weaker pharma competitiveness. Older-Persons Awareness: International Senior Citizens Day (Oct 1) highlights dignity, health and well-being for older adults.

EADV in Vienna (Sept 30–Oct 3): New dermatology data are piling up fast, with AbbVie reporting Phase 2 results for zumilokibart in atopic dermatitis (improved skin and itch, with the mid-dose moving to Phase 3) and Highlight Therapeutics touting intralesional BO-112 for localized basal cell carcinoma (61% visual+pathologic response at week 24). Long-term eczema progress: Galderma says nemolizumab (Nemluvio) maintained improvements in lesions, itch and quality of life through 3 years in the ARCADIA extension. Skin safety online: A study flagged that nearly 95% of viral Korean skincare TikTok videos contain misleading claims, with basic safety info largely missing—raising risks like irritation and barrier damage. Hearing tech: Austrian MED-EL launched the TICI UNICO, billed as the world’s first commercially available fully implanted cochlear implant. Public health focus: Experts warn Europe is not on track to meet antimicrobial resistance targets, urging stronger prescription regulation. Austria policy: The EU Commission approved Austria’s final NextGenerationEU payment request (€306m), marking completion of remaining milestones.

EU Recovery Milestone for Austria: The European Commission has approved Austria’s fifth and final Recovery and Resilience Facility payment request (€306m), saying all remaining milestones and targets are now met—covering decarbonisation, sustainable mobility, circular economy, biodiversity, plus innovation and culture. Dermatology in Vienna (EADV 2026): Multiple drug updates are set for the European Academy of Dermatology and Venereology Congress in Austria, including Enveda’s late-breaking Phase 1b mechanistic/biomarker data for atopic dermatitis (ENV-294), Galderma’s 3-year ARCADIA extension results for nemolizumab (Nemluvio), and Egle’s Phase 1 data for the Treg-selective IL-2 agonist EGL-003. Public health & lifestyle policy debate: Coverage highlights growing pressure in Europe to tackle ultra-processed foods and tobacco, alongside sugary drink tax discussions—notes that Austria currently lacks a sugar tax but the topic remains politically sensitive. Health research signal: A German-Austrian study reports microplastics can impair liver immune cells in mice, disrupting metabolism and increasing fat buildup.

New Hearing Tech in Austria: MED-EL (Innsbruck) launched TICI UNICO, a CE-marked “totally invisible” cochlear implant with all components under the skin, aiming for 24/7 hearing without external processors. Microplastics & Liver Health: A German-Austrian study (University of Bonn) reports microplastics can impair liver immune cells in mice, disrupting metabolism and increasing fat buildup—published in Nature Metabolism. Sleep & Serious Risks: A large European umbrella review links insomnia to higher stroke risk (about +26%) and greater hospital admissions, with added associations to dementia and suicidal behavior. Medical Imaging in Vienna: United Imaging Healthcare received CE marking for uPMR Zenith, a PET/MR system planned for clinician showcase in Vienna (Oct 17–21). Data Quality for Better AI Drugs: Researchers at the University of Vienna developed an automated statistical method to flag hidden anomalies in scientific datasets, using Benford’s Law to improve reliability for AI-driven research. Public Health & Skin Care: A case report describes allergic contact dermatitis triggered by benzyl alcohol in moist toilet paper—highlighting how everyday products can drive eczema. Health Policy Context: Austria’s October 2026 changes include a “regulation freeze” push that could reshape how EU health and safety rules are implemented.

Clinical Breakthrough in Austria: Cyprumed (Innsbruck) says MSD has started a Phase I trial of an oral peptide drug candidate using Cyprumed’s oral tablet delivery tech—its first technology program to enter human studies, with a milestone payment triggered. Sleep & Brain Health: A new international review linked insomnia with higher stroke risk (+26%), more depression and suicide attempts, and higher odds of hospital admission—researchers include teams from Austria and MedUni Vienna. Vienna Conference Spotlight: Belite Bio will present retinal disease data at Euretina Innovation Spotlight and Euretina in Vienna, including Phase 3 DRAGON results for adolescent Stargardt disease. Policy & Public Health Debate: Austria’s Red Bull keeps fighting India’s regulator over the “energy drink” label; the Delhi High Court quashed FSSAI’s ban for lack of a chance to be heard, while FSSAI signals it may appeal. Health Systems & Implementation: At the Gastein health conference, leaders warn Europe’s problem isn’t ideas—it’s slow implementation of health policy.

Sleep & Brain Health: A new international review with MedUni Vienna links insomnia to higher health risks, including a 26% increased risk of stroke and about 28% higher odds of hospital admission, with associations also reported for dementia and mental health problems. Dermatology in Vienna: Attovia Therapeutics will present new clinical and preclinical data in Vienna at EADV 2026, including updates on its anti-IL-31 programs ATTO-1310 and ATTO-2306. AI in Healthcare (Austria): DermaSensor launches in Germany via ContraCare, with distribution planned for Germany, Austria and Switzerland—aimed at AI-assisted skin cancer risk detection for dermatology practices. Access to Care (Optometry): MyEyeDr. says it will acquire EyeCare Partners’ optometry division (300+ offices), expanding eye care capacity and services. Reproductive Health Policy (Austria): Women’s Minister Eva-Maria Holzleitner renews calls for nationwide abortion protection zones to curb harassment near clinics. Cross-border Emergency Care: Austria and Hungary move toward smoother day-to-day emergency coordination for incidents across the border. Education & Admissions (Linz): JKU Linz adds an in-person competence check for applicants who studied in Bangladesh, India or Pakistan starting summer 2027. Public Health Safety: Travel Health Pro reports a potentially lethal West Nile virus outbreak across 16 European countries, urging prevention measures.

Clinical Research in Austria: JJP Biologics will present interim Phase Ib proof-of-concept data for nebaprubart (anti-CD89) in linear IgA dermatosis at the IPPF Scientific Symposium in Lübeck and at EADV 2026 in Vienna, positioning the therapy for IgA-mediated autoimmune skin diseases. Sleep & Stroke Risk: A new review in Sleep Medicine Reviews links insomnia with a 26% higher stroke risk and higher odds of hospital admission, adding to concerns that poor sleep can signal broader brain and mental health problems. Public Health Alert (Europe): France is investigating a Salmonella Enteritidis outbreak tied to pumpkin seeds, with 81 reported cases and investigators noting how long shelf life and mixed snack use can complicate tracing. Health Policy & Ethics: Pope Leo XIV condemned assisted suicide and euthanasia during a visit to Lourdes, arguing that legal permission doesn’t make ending life “moral.” Austria in the News (Housing): A report highlights Vienna’s social housing model as a response to rent pressure across Europe.